-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
inflammatory -X- _ O
response -X- _ O
in -X- _ O
pneumococcal -X- _ O
infection -X- _ O
is -X- _ O
primarily -X- _ O
driven -X- _ O
by -X- _ O
immunoreactive -X- _ O
bacterial -X- _ O
cell -X- _ O
wall -X- _ O
components -X- _ O
[ -X- _ O
lipoteichoic -X- _ O
acid -X- _ O
( -X- _ O
LTA -X- _ O
) -X- _ O
] -X- _ O
. -X- _ O
An -X- _ O
acute -X- _ O
release -X- _ O
of -X- _ O
these -X- _ O
components -X- _ O
occurs -X- _ O
when -X- _ O
pneumococcal -X- _ O
infection -X- _ O
is -X- _ O
treated -X- _ O
with -X- _ O
β-lactam -X- _ O
antibiotics. -X- _ O
OBJECTIVES -X- _ O
: -X- _ O
We -X- _ O
hypothesized -X- _ O
that -X- _ O
non-lytic -X- _ B-Intervention
rifampicin -X- _ I-Intervention
compared -X- _ I-Intervention
with -X- _ I-Intervention
lytic -X- _ I-Intervention
β-lactam -X- _ I-Intervention
antibiotic -X- _ I-Intervention
treatment -X- _ I-Intervention
would -X- _ O
attenuate -X- _ O
the -X- _ O
inflammatory -X- _ O
response -X- _ O
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
pneumococcal -X- _ I-Patient
pneumonia. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
In -X- _ O
the -X- _ O
PRISTINE -X- _ O
( -X- _ O
Pneumonia -X- _ O
treated -X- _ O
with -X- _ O
RIfampicin -X- _ O
aTtenuates -X- _ O
INflammation -X- _ O
) -X- _ O
trial -X- _ O
, -X- _ O
a -X- _ O
randomized -X- _ O
, -X- _ O
therapeutic -X- _ O
controlled -X- _ O
, -X- _ O
exploratory -X- _ O
study -X- _ O
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
community-acquired -X- _ I-Patient
pneumococcal -X- _ I-Patient
pneumonia -X- _ I-Patient
, -X- _ O
we -X- _ O
looked -X- _ O
at -X- _ O
LTA -X- _ O
release -X- _ O
and -X- _ O
inflammatory -X- _ O
and -X- _ O
clinical -X- _ O
response -X- _ O
during -X- _ O
treatment -X- _ O
with -X- _ O
both -X- _ O
rifampicin -X- _ B-Intervention
and -X- _ I-Intervention
β-lactam -X- _ I-Intervention
compared -X- _ O
with -X- _ O
treatment -X- _ O
with -X- _ O
β-lactam -X- _ B-Comparison
antibiotics -X- _ I-Comparison
only. -X- _ O
The -X- _ O
trial -X- _ O
is -X- _ O
registered -X- _ O
in -X- _ O
the -X- _ O
Dutch -X- _ O
trial -X- _ O
registry -X- _ O
, -X- _ O
number -X- _ O
NTR3751 -X- _ O
( -X- _ O
European -X- _ O
Clinical -X- _ O
Trials -X- _ O
Database -X- _ O
number -X- _ O
2012-003067-22 -X- _ O
) -X- _ O
. -X- _ O
RESULTS -X- _ O
: -X- _ O
Forty-one -X- _ B-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
community- -X- _ I-Outcome
acquired -X- _ I-Outcome
pneumonia -X- _ I-Outcome
were -X- _ I-Outcome
included -X- _ I-Outcome
; -X- _ I-Outcome
17 -X- _ I-Outcome
of -X- _ I-Outcome
them -X- _ I-Outcome
had -X- _ I-Outcome
pneumococcal -X- _ I-Outcome
pneumonia. -X- _ I-Outcome
LTA -X- _ I-Outcome
release -X- _ I-Outcome
, -X- _ I-Outcome
LTA- -X- _ I-Outcome
mediated -X- _ I-Outcome
inflammatory -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
clinical -X- _ I-Outcome
outcomes -X- _ I-Outcome
, -X- _ I-Outcome
inflammatory -X- _ I-Outcome
biomarkers -X- _ I-Outcome
and -X- _ I-Outcome
transcription -X- _ I-Outcome
profiles -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
different -X- _ I-Outcome
between -X- _ I-Outcome
treatment -X- _ I-Outcome
groups. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
PRISTINE -X- _ O
study -X- _ O
demonstrated -X- _ O
the -X- _ O
feasibility -X- _ O
of -X- _ O
adding -X- _ O
rifampicin -X- _ O
to -X- _ O
β-lactam -X- _ O
antibiotics -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
community-acquired -X- _ O
pneumococcal -X- _ O
pneumonia -X- _ O
, -X- _ O
but -X- _ O
, -X- _ O
despite -X- _ O
solid -X- _ O
in -X- _ O
vitro -X- _ O
and -X- _ O
experimental -X- _ O
animal -X- _ O
research -X- _ O
evidence -X- _ O
, -X- _ O
failed -X- _ O
to -X- _ O
demonstrate -X- _ O
a -X- _ O
difference -X- _ O
in -X- _ O
plasma -X- _ O
LTA -X- _ O
concentrations -X- _ O
and -X- _ O
subsequent -X- _ O
inflammatory -X- _ O
and -X- _ O
clinical -X- _ O
responses. -X- _ O
Most -X- _ O
likely -X- _ O
, -X- _ O
an -X- _ O
inhibitory -X- _ O
effect -X- _ O
of -X- _ O
human -X- _ O
plasma -X- _ O
contributes -X- _ O
to -X- _ O
the -X- _ O
low -X- _ O
immune -X- _ O
response -X- _ O
in -X- _ O
these -X- _ O
patients. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
LTA -X- _ O
plasma -X- _ O
concentration -X- _ O
could -X- _ O
be -X- _ O
too -X- _ O
low -X- _ O
to -X- _ O
mount -X- _ O
a -X- _ O
response -X- _ O
via -X- _ O
Toll-like -X- _ O
receptor -X- _ O
2 -X- _ O
in -X- _ O
vitro -X- _ O
, -X- _ O
but -X- _ O
may -X- _ O
nonetheless -X- _ O
have -X- _ O
an -X- _ O
effect -X- _ O
in -X- _ O
vivo -X- _ O
. -X- _ O

